



RECEIVED

MAR 17 2003

TECH CENTER 1600/2900

RESPONSE UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1616

S/N 09/713,780

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Uckun	Examiner:	Pak, J.
Serial No.:	09/713,780	Group Art Unit:	1616
Filed:	November 15, 2000	Docket No.:	12152.109US01
Title:	VANADIUM COMPOUNDS AS ANTI-ANGIOGENIC AGENTS		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Box AF, Commissioner for Patents, Washington, D.C. 20231, on March 27, 2003.

By:

Teresa D. Morgan

Name: *Teresa D. Morgan*

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116

Box AF
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action dated January 15, 2003, Applicant respectfully requests entry and consideration of the following amendment and remarks. No issues not previously considered by the Examiner are raised herein.

In the Claims

Please amend claim 1 as follows.

1. (AMENDED) A method for inhibiting angiogenesis in a non-cancerous tissue comprising administering to a subject an effective angiogenesis inhibiting amount of a vanadium compound having the following structure: